Impact of novel anti-seizure medications on status epilepticus in Dravet syndrome: a multicenter real-world cohort study.
PURPOSE Status epilepticus (SE) is a major contributor to morbidity in Dravet syndrome (DS). The impact of recently introduced anti-seizure medications (ASMs)-stiripentol (STP), fenfluramine (FFA), and cannabidiol (CBD)-on SE burden remains incompletely defined. We aimed to characterize acute SE management and evaluate...